Quizartinib + Mao Inhibitors Interaction
Moderateinteraction on record
Description
Concomitant use increases quizartinib systemic exposure, which may increase risk of adverse reactions. VANFLYTA dosage reduction recommended.
Mechanism
CYP3A inhibition increases systemic exposure
Source: NLP:quizartinib